The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a is a research paper published in Journal for ImmunoTherapy of Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 59 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Surface Oncology, Inc.
Grant: N/A
FWCI
2.73
Citation Percentile
0.9%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Additional file 1 of CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Additional file 2 of CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Additional file 2 of CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
Additional file 1 of Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile
Additional file 1 of Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile